Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

NeoStem, Inc. (NYSE MKT: NBS), Another PCT Agreement

MedStar Georgetown University Hospital will use the services of PCT for processing and storage of peripheral blood progenitor cells, donor leukocytes, bone marrow and cord blood, as well as requested assaying and storage of cellular therapy product, and retrieval and transportation logistics.

The Georgetown Lombardi Comprehensive Cancer Center at MedStar Georgetown University Hospital is the Washington, D.C. metropolitan region's only comprehensive cancer center, a designation from the National Cancer Institute (NYSE:NCI) demonstrating its scientific excellence and the capability to integrate multi-disciplinary, collaborative research approaches to focus on the problem of cancer. Since its founding, PCT has provided cell therapy products for infusion into over 6,000 patients.

The Bottom Line: Will enable PCT to provide cell products to MedStar Georgetown University Hospital <a very prestigious medical facility> and HackensackUMC to support their bone marrow transplant programs.

NBS closed at $0.56 on 4/10 on solid volume <1.01 M shares> which was UP +$0.03 from 4/9/13. I would rather see incremental movement in revenue … and share pricing than abrupt peaks and valleys as we anticipate a lower opening and DOWN day in the market.

Addendum: NBS is UP +$0.02 or +3.46% to $0.58.

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.